A detailed history of Welch & Forbes LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Welch & Forbes LLC holds 196,619 shares of VRTX stock, worth $80.3 Million. This represents 1.18% of its overall portfolio holdings.

Number of Shares
196,619
Previous 194,897 0.88%
Holding current value
$80.3 Million
Previous $91.4 Million 0.1%
% of portfolio
1.18%
Previous 1.25%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

BUY
$460.0 - $505.78 $792,120 - $870,953
1,722 Added 0.88%
196,619 $91.4 Million
Q2 2024

Aug 01, 2024

BUY
$392.81 - $485.53 $768,336 - $949,696
1,956 Added 1.01%
194,897 $91.4 Million
Q1 2024

May 02, 2024

BUY
$407.69 - $446.08 $1.86 Million - $2.03 Million
4,554 Added 2.42%
192,941 $80.7 Million
Q4 2023

Feb 06, 2024

BUY
$343.0 - $410.68 $1.14 Million - $1.36 Million
3,317 Added 1.79%
188,387 $76.7 Million
Q3 2023

Nov 02, 2023

BUY
$338.18 - $362.46 $89,955 - $96,414
266 Added 0.14%
185,070 $64.4 Million
Q2 2023

Jul 28, 2023

SELL
$314.42 - $351.91 $444,589 - $497,600
-1,414 Reduced 0.76%
184,804 $65 Million
Q1 2023

Apr 14, 2023

SELL
$283.23 - $323.1 $553,148 - $631,014
-1,953 Reduced 1.04%
186,218 $58.7 Million
Q4 2022

Feb 02, 2023

SELL
$285.76 - $321.48 $367,773 - $413,744
-1,287 Reduced 0.68%
188,171 $54.3 Million
Q3 2022

Oct 28, 2022

SELL
$273.83 - $305.53 $759,878 - $847,845
-2,775 Reduced 1.44%
189,458 $54.9 Million
Q2 2022

Jul 22, 2022

SELL
$234.96 - $292.55 $781,242 - $972,728
-3,325 Reduced 1.7%
192,233 $54.2 Million
Q1 2022

Apr 25, 2022

BUY
$221.42 - $260.97 $1.25 Million - $1.47 Million
5,628 Added 2.96%
195,558 $51 Million
Q4 2021

Jan 19, 2022

SELL
$177.01 - $223.45 $2.14 Million - $2.71 Million
-12,107 Reduced 5.99%
189,930 $41.7 Million
Q3 2021

Oct 13, 2021

SELL
$181.39 - $202.99 $785,781 - $879,352
-4,332 Reduced 2.1%
202,037 $36.6 Million
Q2 2021

Jul 22, 2021

SELL
$187.49 - $221.1 $620,779 - $732,062
-3,311 Reduced 1.58%
206,369 $41.6 Million
Q1 2021

Apr 14, 2021

BUY
$207.02 - $241.31 $3.79 Million - $4.42 Million
18,312 Added 9.57%
209,680 $45.1 Million
Q4 2020

Jan 20, 2021

BUY
$207.01 - $276.09 $1.38 Million - $1.85 Million
6,686 Added 3.62%
191,368 $45.2 Million
Q3 2020

Oct 23, 2020

SELL
$255.65 - $303.1 $464,260 - $550,429
-1,816 Reduced 0.97%
184,682 $50.3 Million
Q2 2020

Jul 15, 2020

BUY
$225.48 - $295.8 $931,457 - $1.22 Million
4,131 Added 2.27%
186,498 $54.1 Million
Q1 2020

Apr 17, 2020

BUY
$199.77 - $247.81 $1.5 Million - $1.86 Million
7,499 Added 4.29%
182,367 $43.4 Million
Q4 2019

Jan 17, 2020

SELL
$166.71 - $223.91 $274,404 - $368,555
-1,646 Reduced 0.93%
174,868 $38.3 Million
Q3 2019

Oct 11, 2019

BUY
$166.23 - $187.09 $97,577 - $109,821
587 Added 0.33%
176,514 $29.9 Million
Q2 2019

Jul 12, 2019

BUY
$164.61 - $190.37 $243,128 - $281,176
1,477 Added 0.85%
175,927 $32.3 Million
Q1 2019

Apr 29, 2019

SELL
$163.73 - $194.7 $261,967 - $311,520
-1,600 Reduced 0.91%
174,450 $32.1 Million
Q4 2018

Feb 05, 2019

SELL
$151.91 - $192.21 $58,637 - $74,193
-386 Reduced 0.22%
176,050 $29.2 Million
Q3 2018

Oct 17, 2018

BUY
$167.73 - $192.74 $644,921 - $741,085
3,845 Added 2.23%
176,436 $34 Million
Q2 2018

Jul 16, 2018

SELL
$145.72 - $169.96 $648,454 - $756,322
-4,450 Reduced 2.51%
172,591 $29.3 Million
Q1 2018

Apr 12, 2018

SELL
$151.6 - $177.13 $183,739 - $214,681
-1,212 Reduced 0.68%
177,041 $28.9 Million
Q4 2017

Jan 26, 2018

SELL
$137.28 - $155.55 $332,354 - $376,586
-2,421 Reduced 1.34%
178,253 $26.7 Million
Q3 2017

Nov 13, 2017

BUY
$148.13 - $162.24 $26.8 Million - $29.3 Million
180,674
180,674 $27.5 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Welch & Forbes LLC Portfolio

Follow Welch & Forbes LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Welch & Forbes LLC, based on Form 13F filings with the SEC.

News

Stay updated on Welch & Forbes LLC with notifications on news.